FRI0493 THE INTERLEUKIN-1B INHIBITOR CANAKINUMAB FOR REFRACTORY STILL'S DISEASE: LONG-TERM EXPERIENCE IN 50 CONSECUTIVE PATIENTS

Katerina Laskari, Panagiotis Athanassiou, A. Georgiadis, Charalampos Gerodimos, G. Gkoni, Dimitrios Daoussis, Theodoros Dimitroulas, Despoina Dimopoulou, Chrisoula Iliou, I. Kallitsakis, D. Karamitsos, Christina Katsiari, Stamatis‐Nick C. Liossis, C. Mavragani, Charalampos Papagoras, Dimitrios Pikazis, Ioannis Raftakis, T. Sarikoudis, L. Settas, Prodromos Sidiropoulos, D. Soukera, Evangelos A. Theodorou, P. Tsatsani, Eleni Tsiakou, Dimitrios Vassilopoulos, Panayiotis G. Vlachoyiannopoulos, G. Vosvotekas, Paraskevi V. Voulgari, Marina Zakalka, Maria G. Tektonidou, Petros P. SfikakisAnnals 2020 · DOI

Abstract

Still’s disease is a systemic autoinflammatory disorder that often becomes refractory to conventional treatments. This study (FRI0493) evaluates the long-term efficacy and safety of canakinumab, an interleukin-1β (IL-1β) inhibitor, in a real-world cohort of 50 patients. Results indicate high rates of complete remission (78%) and significant steroid-sparing effects, though tapering remains a clinical challenge.

Introduction

Still’s disease, which includes Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (sJIA), is characterized by high-grade fevers, evanescent rashes, and arthritis. The pathophysiology is heavily driven by a "cytokine storm," with Interleukin-1 (IL-1) playing a central role. While corticosteroids and methotrexate are first-line therapies, many patients fail to achieve sustained remission or become steroid-dependent. Canakinumab, a human monoclonal antibody targeting IL-1β, offers a targeted approach for these difficult-to-treat cases. This study provides long-term, real-world data on its use in a refractory population.

Methods

This retrospective longitudinal study analyzed 50 consecutive patients (age range 14–72 years) treated at various rheumatology centers in Greece. All participants met the Yamaguchi classification criteria and had failed previous treatments, including corticosteroids, methotrexate, and other biologics; notably, 60% of the cohort had failed at least one prior biologic. Patients received canakinumab subcutaneously at doses of 150–300 mg every 4 to 8 weeks. The median follow-up period was 24 months, with some patients monitored for up to 84 months (7 years).

Results

Efficacy and Remission

Canakinumab demonstrated rapid and high efficacy in this refractory population. Complete remission was achieved by 78% of the cohort within a median of just 3 months. An additional 20% of patients showed a partial clinical and laboratory response. Only one patient (2%) was identified as a primary non-responder.

Steroid-Sparing Effect

A critical outcome was the drug's ability to reduce the burden of chronic corticosteroid use. Over the course of the study, 51% of patients were able to successfully discontinue steroids entirely, significantly reducing the risk of long-term complications such as osteoporosis, weight gain, and diabetes.

Tapering and Durability

The response to canakinumab was durable over the long term. However, treatment discontinuation proved challenging; of the 19 patients who attempted to stop the drug after reaching remission, 8 (42%) experienced a relapse. In most instances, re-initiating canakinumab successfully restored remission.

Safety Profile

The safety profile was consistent with previous clinical reports. Infections occurred in 20% of patients, with 4% classified as severe. Leucopenia was noted in 6% of the cohort. Only one patient discontinued treatment specifically due to an adverse event.

Discussion

The findings from this Greek cohort represent the largest real-world study of canakinumab in refractory Still’s disease to date. The data suggest that canakinumab is equally effective across different age groups and disease durations. The rapid onset of action is particularly noteworthy for a population that has struggled with active disease despite multiple prior therapies.

The high relapse rate upon discontinuation (42%) highlights the need for standardized tapering protocols. While the drug is highly effective at inducing and maintaining remission, the optimal strategy for withdrawal remains unclear and requires further prospective investigation.

Conclusion

Canakinumab is a potent and durable treatment option for refractory Still’s disease, offering a high probability of complete remission and a significant steroid-sparing benefit. While safety concerns such as infections exist, they are manageable for the majority of patients. Future research should focus on optimizing dose tapering to maintain long-term remission without indefinite biologic use.

Summary updated

BibTeX
@article{laskari2020fri,
  author = {Katerina Laskari and Panagiotis Athanassiou and A. Georgiadis and Charalampos Gerodimos and G. Gkoni and Dimitrios Daoussis and Theodoros Dimitroulas and Despoina Dimopoulou and Chrisoula Iliou and I. Kallitsakis and D. Karamitsos and Christina Katsiari and Stamatis‐Nick C. Liossis and C. Mavragani and Charalampos Papagoras and Dimitrios Pikazis and Ioannis Raftakis and T. Sarikoudis and L. Settas and Prodromos Sidiropoulos and D. Soukera and Evangelos A. Theodorou and P. Tsatsani and Eleni Tsiakou and Dimitrios Vassilopoulos and Panayiotis G. Vlachoyiannopoulos and G. Vosvotekas and Paraskevi V. Voulgari and Marina Zakalka and Maria G. Tektonidou and Petros P. Sfikakis},
  title = {{FRI0493 THE INTERLEUKIN-1B INHIBITOR CANAKINUMAB FOR REFRACTORY STILL'S DISEASE: LONG-TERM EXPERIENCE IN 50 CONSECUTIVE PATIENTS}},
  journal = {Annals},
  year = {2020},
  doi = {10.1136/annrheumdis-2020-eular.5217},
}
Figure